The first phase of clinical studies on UAE-made insulin was a success, Gulf Pharmaceutical Industries – Julphar has said.
The local product showed significant similarity to a product licensed in the European Union, making it a viable alternative, reported Al Ittihad, the Arabic-language sister newspaper of The National.
Dr Ayman Al Sahli, Julphar’s executive chairman, said the study was authorised by the German pharmaceutical authority.
newsdesk@thenational.ae
